Calcium signaling as a molecular target in cancer

Pharmaceutical News

Volumn 9, Issue 6, 2002, Pages 435-442

  Kamrava, Mitchell R ^a   Michener, Chad M ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Invasion; Signal transduction; Tumor growth

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CYTOKINE; IMIDAZOLE; TRIAZOLE; TUMOR MARKER; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; CALCIUM BALANCE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CARCINOMA; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; METASTASIS; MOLECULAR DYNAMICS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0042193225     PISSN: 1071894X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Liotta, L.A. and Kohn, E.C. (2001). The microenvironment of the tumor-host invasion field. Nature 411, 375-379.
2. Hanahan, D. and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
3. Kohn, E.C. and Liotta, L.A. (1995). Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55, 1856-1862.
4. Mills, G.B., Lu, Y., and Kohn, E.C. (2001). Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the phosphatidylinositol 3 kinase pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 98, 10031-10033.
5. Spiegel, A.M. (1988). G proteins in clinical medicine. Hosp Pract (Off Ed) 23, 93-100, 105-106, 111-102.
6. Felder, C.C., Singer-Lahat, D., and Mathes, C. (1994). Voltage-independent calcium channels. Regulation by receptors and intracellular calcium stores. Biochem Pharmacol, 48, 1997-2004.
7. Berridge, M. (1995). Calcium signaling and cell proliferation. Bioessays 17, 491-500.
8. Berridge, M.J. (1997). Elementary and global aspects of calcium signaling. Journal of Physiology 499, 290-306.
9. Kerbel, R.S., Waghome, C., Man, M.S., Elliott, B., and Breitman, M. L. (1987). Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection. Proc Natl Acad Sci U S A 84, 1263-1267.
10. Takemura, H., Hughes, A.R., Thastrup, O., and Putney, J.W. (1989). Activation of calcium entry by the tumor promoter thapsigargin in parotid acinar cells. J Biol Chem 264, 12266-12271.
11. Rodland, K.D., Wersto, R.P., Hobson, S., and Kohn, E.C. (1997). Thapsigargin-induced gene expression in non-excitable cells is dependent on calcium influx. Mol Endocrinol 11, 281-291.
12. Felder, C.C., MacArthur, L., Ma, A.L., Gusovsky, F., and Kohn, E.C. (1993). Tumor-suppressor function of muscarinic acetylcholine receptors is associated with activation of receptor-operated calcium influx. Proc Natl Acad Sci U S A 90, 1706-1710.
13. Liotta, L.A., Mandler, R., Murano, G., Katz, D.A., Gordon, R.K., Chiang, P.K., and Schiffmann, E. (1986). Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A 83, 3302-3306.
14. Levine, M.D., Liotta, L.A., and Stracke, M.L. (1995). Stimulation and regulation of tumor cell motility in invasion and metastasis. EXS 74, 157-179.
15. Silletti, S. and Raz, A. (1993). Autocrine motility factor is a growth factor. Biochem Biophys 194, 446-457.
16. Nam, S.W., Clair, T., Kim, Y.S., McMarlin, A., Schiffmann, E., Liotta, L.A., and Stracke, M.L. (2001). Autotaxin (NPP-2), a metastasis-enhancing mitogen, is an angiogenic factor. Cancer Res 61, 6938-6944.
17. Seiki, M., Sato, H., Liotta, L.A., and Schiffmann, E. (1991). Comparison of autocrine mechanisms promoting motility in two metastatic cell lines: human melanoma and ras-transfected NIH3T3 cells. Int J Cancer 49, 717-720.
18. Fang, X., Gaudette, D., Furui, T., Mao, M., Estrella, V., Eder, A., Pustilnik, T., Sasagawa, T., Lapushin, R., Yu, S., Jaffe, R.B., Wiener, J.R., Erickson, J.R., and Mills, G.B. (2000). Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci 905, 188-208.
19. Umezu-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., Yamori, T., Mills, G.B., Inoue, K., Aoki, J., and Arai, H. (2002). Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158, 227-233.
20. Daub, H., Weiss, F.U., Wallasch, C., and Ullrich, A. (1996). Role of transactivation of the EGF receptro in signalling by G-protien-coupled receptors. Nature 379, 557-560.
21. Berridge, M.J. (1984). Inositol trisphosphate and diacylglycerol as second messengers. Biochem J 220, 345-360.
22. Doong, H., Price, J., Kim, Y.S., Gasbarre, C.C., Probst, J., Liotta, L.A., Blanchette, J., Rizzo, K., and Kohn, E.C. (2000). CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-g and Hsp70/Hsc70. Oncogene 19(38), 4385-95.
23. Carpenter, G. (2000). The EGF receptor: a nexus for trafficking and signaling. Bioessays 22, 697-707.
24. Herbst, R.S. and Shin, D.M. (2002). Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94, 1593-1611.
25. Yang, L., Camoratto, A.M., Baffy, G., Raj, S., Manning, D.R., and Williamson, J.R. (1993). Epidermal growth factor-mediated signaling of G(i)-protein to activation of phospholipases in rat-cultured hepatocytes. J Biol Chem 268, 3739-3746.
26. Kadowaki, T., Koyasu, S., Nishida, E., Tobe, K., Izumi, T., Takaku, F., Sakai, H., Yahara, I., and Kasuga, M. (1987). Tyrosine phosphorylation of common and specific sets of cellular proteins rapidly induced by insulin, insulin-like growth factor I, and epidermal growth factor in an intact cell. J Biol Chem 262, 7342-7350.
27. Kojima, I., Kitaoka, M., and Ogata, E. (1990). Insulin-like growth factor-I stimulates diacylglycerol production via multiple pathways in Balb/c 3T3 cells. J Biol Chem 265, 16846-16850.
28. Kohn, E.C. and Liotta, L.A. (1990). L651582, a novel anti-proliferative and antimetastasis agent. J Natl Cancer Inst 82, 54-60.
29. Kohn, E.C., Sandeen, M.A., and Liotta, L.A. (1992). In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 52, 3208-3212.
30. Kohn, E.C., Felder, C.C., Jacobs, W., Holmes, K.A., Day, A., Freer, R., and Liotta, L.A. (1994). Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 54, 935-942.
31. Kamaluddin, M., McNally, P., Breatnach, F., O'Marcaigh, A., Webb, D., O'Dell, E., Scanlon, P., Butler, K., and O'Meara, A. (2001). Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 90, 1204-1207.
32. Ayub, M., and Levell, M.J. (1987). Inhibition of rat testicular 17 alpha-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro. J Steroid Biochem 28, 43-47.
33. Ayub, M., and Levell, M.J. (1987). Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J Steroid Biochem 28, 521-531.
34. Stalla, G.K., Stalla, J., von Werder, K., Muller, O.A., Gerzer, R., Hollt, V., and Jakobs, K.H. (1989). Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology 125, 699-706.
35. Gupta, S., Kim, J., and Gollapudi, S. (1991). Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. J Clin Invest 87, 1467-1469.
36. Najid, A. and Ratinaud, M.H. (1991). Comparative studies of steroidogenesis inhibitors (econazole, ketoconazole) on human breast cancer MCF-7 cell proliferation by growth experiments, thymidine incorporation and flow cytometric DNA analysis. Tumori 77, 385-390.
37. Bruserud, O. (2001). Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia. Int Immunopharmacol 1, 2183-2195.
38. Alonso-Torre, S.R., Alvarez, J., Montero, M., Sanchez, A., and Garcia-Sancho, J. (1993). Control of Ca2+ entry into HL60 and U937 human leukaemia cells by the filling state of the intracellular Ca2+ stores. Biochem J 289:761-766.
39. Villalobos, C., Fonteriz, R., Lopez, M.G., Garcia, A.G., and Garcia-Sancho, J. (1992). Inhibition of voltage-gated Ca2+ entry into GH3 and chromaffin cells by imidazole antimycotics and other cytochrome P450 blockers. FASEB J 6, 2742-2747.
40. Hornstein, E.H., Vassilopoulos, D., Thomas, D.E., Friedman, F.K., and Tsokos, G.C. (1996). Modulation of human T-lymphocyte plasma membrane Ca2+ permeability by imidazole antimycotics. Immunopharmacol Immunotoxicol 18, 237-245.
41. Coupry, I., Armsby, C.C., Alper, S.L., Brugnara, C., and Parini, A. (1996). Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I1 and I2 binding sites. Eur J Pharmacol 2295, 109-112.
42. Brugnara, C., Armsby, C.C., Sakamoto, M., Rifai, N., Alper, S.L., and Platt, O. (1995). Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther 273, 266-272.
43. Alvarez, J., Montero, M., and Garcia-Sancho, J. (1992). Cytochrome P450 may regulate plasma membrane Ca2+ permeability according to the filling state of the intracellular Ca2+ stores. FASEB J 6, 786-792.
44. Sargeant, P., Clarkson, W.D., Sage, S.O., and Heemskerk, J.W. (1992). Calcium influx evoked by Ca2+ store depletion in human platelets is more susceptible to cytochrome P-450 inhibitors than receptor-mediated calcium entry. Cell Calcium 13, 553-564.
45. Alonso, M.T., Alvarez, J., Montero, M., Sanchez, A., and Garcia-Sancho, J. (1991). Agonist-induced Ca2+ influx into human platelets is secondary to the emptying of intracellular Ca2+ stores. Biochem J 280, 783-789.
46. Ludden, L.K., Strong, J.M., Kohn, E.C., and Collins, J.M. (1995). Similarity of metabolism for CAI (NSC 609974) in human liver tissue in vitro and in humans in vivo. Clin Cancer Research 1, 399-405.
47. Benzaquen, L.R., Brugnara, C., Byers, H.R., Gatton-Celli, S., and Halperin, J.A. (1995). Clotrimazole inhibits cell proliferation in vitro and in vivo. Nature Med 1, 534-540.
48. Zhang, Y., Crump, M., and Berge, S.A. (2002). Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death. Breast Cancer Res Treat 72, 265-278.
49. Felder, C.C., Ma, A.L., Liotta, L.A., and Kohn, E.C. (1991). The antiproliferative and antimetastatic compound L651582, inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther 257, 967-971.
50. Gusovsky, F., Lueders, J.E., Kohn, E.C., and Felder, C.C. (1993). Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma: alternative mechanism for cholinergic receptor-induced phosphoinositide breakdown. J Biol Chem 268, 7768-7772.
51. Kohn, E.C., Jacobs, W., Kim, Y.S., Alessandro, R., Stetler-Stevenson, W.G., and Liotta, L.A. (1994). Calcium influx regulates matrix metalloproteinase-2 (72 kDa type IV collagenase, gelatinase A) expression. J Biol Chem 269, 21505-21511.
52. Merritt, J.E., Armstrong, W.P., Benham, C.D., Hallam, T.J., Jacob, R., Jaxa-Chamiec, A., Leigh, B., McCarthy, S.A., Moores, K.E., and Rink, T.J. (1990). SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem J 271, 515-522.
53. Kohn, E.C., Alessandro, R., Spoonster, J., Wersto, R., and Liotta, L.A. (1995). Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci U S A 92, 1307-1311.
54. Spoonster, J.R., Masiero, L., Savage, S.A., Probst, J., and Kohn, E.C. (1997). Regulation of cell spreading during differentiation in the muscarinic m5 receptor tumor suppressor model. Int J Cancer 72, 362-368.
55. Bauer, K.S., Figg, W.D., Hamilton, J.M., Jones, E.C., Premkumar, A., Steinberg, S.M., Dyer, V., Linehan, W.M., Pluda, J.M., and Reed, E.A. (1999). Pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin Cancer Res 5, 2324-2329.
56. Luzzi, K.J., Varghese, H.J., MacDonald, I.C., Kohn, E.C., Schmidt, E.E., Morris, V.L., Chambers, A.F., and Groom, A.C. (1999). Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI): computer assisted analysis. Angiogenesis 2, 373-379.
57. Alessandro, R., Masiero, L., Lapidos, K., Spoonster, J., and Kohn, E.C. (1998). Endothelial cell spreading on type IV collagen and spreading induced FAK phosphorylation is regulated by calcium influx. Biochem Biophys Res Commun 248, 635-640.
58. Masiero, L., Lapidos, K.A., Ambudkar, I., and Kohn, E.C. (1999). Regulation of the RhoA$pathway in human endothelial cell spreading on type IV collagen: role of calcium influx. Journal Cell Sci 112, 3205-3213.
59. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13, 9-22.
60. Kohn, E.C., Reed, E., Sarosy, E., Christian, M., Link, C.J., Cole, K.A., Figg, W.D., Davis, P.A., Jacob, J., Goldspiel, B., and Liotta, L.A. (1996). Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56, 569-573.
61. Kohn, E.C., Figg, W.D., Sarosy, G.A., Bauer, K.S., Davis, P.A., Soltis, M.J., Thompkins, A., Liotta, L.A., and Reed, E. (1997). Phase I trial of micronized formulation CAI in patients with refractory solid tumors: pharmacokinetics, clinical outcome and comparison of formulations. Journal Clin Oncol 15, 1985-1993.
62. Kohn, E.C., Reed, E., Sarosy, G.A., Minasian, L., Bauer, K.S., Bostick-Bruton, F., Kulpa, V., Fuse, E., Tompkins, A., Noone, M., Goldspiel, B., Pluda, J., Figg, W.D., and Liotta, L.A. (2001). A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res 7, 1600-1609.
63. Kulpa, Oliver, V., Patton, A.M., Desai, S., Lorang, D., Libutti, S.K., and Kohn, E.C. (in press). Regulation of the proangiogenic microenvironment by carboxyamido-triazoler. Journal of Cellular Physiology.